TORONTO, April 16, 2026 /CNW/ – Grey Wolf Animal Health Corp. (TSXV:WOLF) (“Grey Wolf” or the “Company”), a Canadian diversified health company, today announced financial results for the fourth quarter and year ended December 31, 2025. All results are reported in Canadian dollars.
Highlights
- Revenue for the quarter increased year over year by 34.3% to $9.0 million. Revenue for the full year increased by 33.3% to $35.8 million for the year.
- Gross profit increased year over year by 38.8% to $4.7 million for the quarter and 38.5% to $19.0 million for the year.
- Adjusted EBITDA1 increased year over year by 79.3% to $1.6 million for the quarter and 61.0% to $6.9 million for the year.
“Grey Wolf delivered strong revenue and Adjusted EBITDA1 growth in 2025″, said Angela Cechetto, Chief Executive Officer. “Our pharmacy business revenue grew by 54.7% to $22.7 million during the year driven by organic growth in our existing compounded products and the full year impact from the CPM Acquisition in December 2024. Excluding the impact of CPM, our pharmacy business posted strong organic growth of 12.7% in 2025 compared to 2024.”
Ms. Cechetto went on to say, “our Animal Health business was up 7.4% to $13.0 million in 2025 as we continue to see solid performance in our behaviour and GI portfolios and new products launched in the past year, as well as an increase in commission revenue. Adjusted EBITDA1 increased by 61.0% to $6.9 million for the year as a result of higher revenue and gross margins, with our Adjusted EBITDA1 margin improving to 19.3% year to date vs 16.0% in the prior year.”
Key Financial Data and Comparative Results
|
Three months ended |
Twelve months ended |
|||
|
Dec 31, 2025 |
Dec 31, 2024 |
Dec 31, 2025 |
Dec 31, 2024 |
|
|
Revenue |
$8,982,177 |
$6,686,705 |
$35,764,742 |
$26,829,485 |
|
Gross profit |
4,663,214 |
3,359,999 |
19,062,269 |
13,758,580 |
|
Gross profit % |
51.9 % |
50.2 % |
53.3 % |
51.3 % |
|
Total operating expenses |
3,838,870 |
3,551,626 |
15,005,511 |
11,853,433 |
|
Operating income (loss) for the period |
824,344 |
(191,627) |
4,056,758 |
1,905,147 |
|
Income tax expense |
80,061 |
82,103 |
720,457 |
687,053 |
|
Net income (loss) for the period |
329,286 |
(501,102) |
1,656,740 |
704,668 |
|
Earnings (loss) per share |
||||
|
Basic and diluted |
$0.01 |
($0.02) |
$0.05 |
$0.02 |
|
EBITDA |
1,530,786 |
285,909 |
6,741,837 |
3,381,065 |
|
Adjusted EBITDA |
1,554,774 |
867,368 |
6,901,142 |
4,286,175 |